Company news

Shanghai Pharmaceuticals Holding Co. Ltd. Class A (SSE:601607) news

Shanghai Pharmaceuticals Holding Co. Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement…

Shanghai Pharmaceuticals Holding Co. Ltd. Class A (SSE:601607) news

Press releases & updates

(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Transfer of Equity Interests in Zeus Investment Limited and Its Affiliates

(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Annual Operating Performance Assessment and Compensation Plan for Senior Executives

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Resolutions of the 5th Meeting of the 9th Board of Directors

(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Isavuconazonium Sulfate for Injection

(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Esomeprazole Magnesium Enteric-coated Capsules

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Paclitaxel Injection

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Implementation of Dividend Distribution for the First Half of 2026

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Ruxolitinib Phosphate Tablets

"Shanghai Pharmaceuticals Holding Co., Ltd."Semi-annual Report for 2026

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Resolutions of the 3rd Meeting of the 9th Board of Directors

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Omeprazole and Sodium Bicarbonate Dry Suspension (I)

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Obtaining Canadian Product Licenses for DRAGON & TIGER Qingliang You Regular (Cooling Ointment), DRAGON & TIGER Qingliang You Ultra (Cooling Ointment) and DRAGON & TIGER Fengyou Jing Oil (Roll-On Medicated Oil)

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on the Receipt of Clinical Trial Approval Notice for Qingrun Yangmu Granules

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Resolutions of the 2nd Meeting of the 9th Board of Directors

"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Implementation of Dividend Distribution for 2025

"Shanghai Pharmaceuticals Holding Co., Ltd."Correction Announcement for the Announcement on Resolutions of the 2025 Annual General Meeting

"Shanghai Pharmaceuticals Holding Co.,Ltd." Announcement on the Completion of Implementation of Controlling Shareholder's Share Increase Plan and Results

Announcement on Obtaining Approval for Production of Vigabatrin Powder for Oral Solution

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Election of Employee Representative Director for the 9th Board of Directors

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Notice on Convening the 2025 Annual General Meeting

Announcement on Subsidiary Becoming the Marketing Authorization Holder of Trazodone Hydrochloride Tablets

Announcement on the Interim Dividend Distribution Arrangement in 2026

Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in Thailand

Report for Q1 2026

Announcement on Progress in Proposed Public Listing and Transfer of 30% Equity in Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd.

Announcement on Prednisolone Tablets Passing Generic Drug Consistency Evaluation

Announcement on Digoxin Tablets Passing Generic Drug Consistency Evaluation

Announcement on Proposed Issuance of Debt Financing Products

Announcement on Convening the 2025 Annual Performance Briefing

Announcement on Completion of Generic Drug Consistency Evaluation for Cefazolin Sodium for Injection

Announcement on Subsidiary Obtaining Philippine Drug Registration Certificate for Pregabalin Capsules

Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in Singapore

Announcement on Independent Exercise Results of Reserved Stock Options in the 3rd Vesting Period of 2019 A-share Stock Option Incentive Plan

Announcement on Obtaining Approval for Production of Sitagliptin and Metformin Hydrochloride Sustained-release Tablets

Announcement on the Receipt of Clinical Trial Approval Notice for Qiling Granules

Announcement on Obtaining Approval for Production of Avatrombopag Maleate Tablets

Announcement on the Receipt of Clinical Trial Approval Notice for B023 Cell Injection Solution

Announcement on Completion of Acquisition of 10% Equity of SIIC Finance Co., Ltd. and Related Party Transactions

Announcement on Obtaining Approval for Production of Pyridostigmine Bromide Oral Solution

Announcement on Independent Exercise Results of Reserved Stock Options in the 3rd Vesting Period of 2019 A-share Stock Option Incentive Plan and in Q4 2025

Acquisition Report

Announcement on Resolutions of the 27th Meeting of the 8th Board of Directors

Announcement on Implementation of Semi-annual Dividend Distribution for 2025

Indicative Announcement on Restricted Exercise Period for the 3rd Exercise Period of the Reserved Stock Options of 2019 A-share Stock Option Incentive Plan

Announcement on Obtaining Philippine Drug Registration Certificate for Hydroxychloroquine Sulfate Tablets

Announcement on the Approval of the Marketing Authorization Application for Sitagliptin Fumarate Tablets (SPH3127 Tablets)

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025